| Title: |
Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study. |
| Authors: |
Duzzi, Laura; Möhn, Nora; Narten, Emily; Thomas, Janin; Mahjoub, Susann; Grote-Levi, Lea; Jendretzky, Konstantin; Nay, Sandra; Konen, Felix; Wiegmann, Jonas; Beutel, Gernot; Fröhlich, Tabea; Bollmann, Benjamin-Alexander; Wirth, Thomas; Wasielewski, Imke von; Heidel, Florian H.; Gutzmer, Ralf; Skripuletz, Thomas; Ivanyi, Philipp; Group)-Investigators, the ICOG (Immune Cooperative Oncology |
| Source: |
Oncology Research; 2026, Vol. 34 Issue 5, p1-17, 17p |
| Subject Terms: |
C-reactive protein; Biomarkers; Immune checkpoint inhibitors; Neurologic manifestations of general diseases; Cancer treatment; Autoimmune diseases; Cohort analysis |
| Abstract: |
Objectives: Since 2011, immune checkpoint inhibitors (ICI) have transformed the treatment of various cancers. However, our understanding of the autoimmune adverse events, particularly those affecting the nervous system, remains limited. These adverse events can cause significant disability or even death, yet there are currently no established guidelines or biomarkers to aid diagnosis and treatment. With this study, we aim to gain a deeper understanding of neurological adverse events and investigate potential predictive biomarkers. Methods: Between 19 December 2019 and 21 August 2021, 150 out of 543 ICI-treated cancer patients were eligible for our prospective monocentric cohort study. Neurological assessments, clinical scores and the severity of side effects were analysed. Blood samples were taken before, during and after therapy. Patients with neurological AEs (the nAE group) and those without (the non-nAE group) were compared to identify potential predictive markers. Results: Of the 150 patients, 55 (36.7%) experienced nAE of any kind or severity, ranging from non-specific neurological symptoms to severe events. Severe nAE (Grade ≥ 3) was observed in 3.3% of patients and included cases of encephalitis and cerebral vasculitis. Regarding potential biomarkers, an increase in C-reactive protein (CRP) within the first 3–4 weeks was statistically associated with an increased likelihood of nAE in this study. As for patient- and treatment-related parameters, concurrent chemotherapy was found to be significantly associated with the occurrence of nAE. Conclusions: This study observed a relatively high rate of nAE under ICI therapy, partly due to the intentionally broad case definition. CRP elevation emerged as a potential predictive biomarker, warranting further investigation. However, other statistically significant markers did not consistently demonstrate clinical relevance. Supplementary Material Supplementary Material File [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Oncology Research is the property of Tech Science Press and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |